Education
About Us
Working with TipRanks
Follow Us
InMed Pharmaceuticals (DE:MWG)
FRANKFURT:MWG
MWG Stock Chart & Stats
€0.85
-€0.14(-2.97%)
At close: 4:00 PM EST
€0.85
-€0.14(-2.97%)
Day’s Range― - ―
52-Week Range€0.61 - €6.60
Previous CloseN/A
Volume0.00
Average Volume (3M)50.00
Market Cap
€2.03M
Enterprise Value-€7.42M
Total Cash (Recent Filing)€9.60M
Total Debt (Recent Filing)€730.14K
Price to Earnings (P/E)―
Beta2.82
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding2,919,186
10 Day Avg. Volume150
30 Day Avg. Volume50
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.64
P/FCF Ratio-0.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet HealthVery low leverage and positive equity reduce insolvency and interest-rate risk, providing financial flexibility to fund R&D or negotiate milestone financing. Over a multi-month horizon, low debt limits covenants and creditor constraints, improving the firm's ability to execute clinical plans.
Lead Program ProgressRobust preclinical efficacy signals, demonstrated oral bioavailability and planned FDA pre-IND engagement create a clear, multi-step development roadmap. These milestones (IND-enabling studies, pre-IND, Phase 1 target) materially de-risk timelines and support durable value creation if clinical translation holds.
Manufacturing & Biosynthesis CapabilitiesIn-house biosynthesis and manufacturing expertise supports lower trial supply risk, potential contract manufacturing revenue, and faster formulation scale-up. Structurally this capability increases optionality for partnerships, licensing or CMO services and can bolster margins if commercialized.
Bears Say
Persistent Cash BurnOngoing negative operating and free cash flow creates a sustained funding need, raising dilution risk and constraining multi-year R&D plans. With volatile FCF trends and large TTM outflows, the company must secure external capital to sustain IND-enabling work and trials, affecting strategic optionality.
No Recurring Product RevenueAbsent material commercial sales, the firm relies on equity or financing to fund operations. This structural revenue gap increases dependence on capital markets or partners, heightens dilution risk, and leaves execution tied to successful clinical milestones rather than sustainable cash generation.
Regulatory-Driven Business ContractionLegislative change forced exit from a commercial segment, removing a revenue and diversification source and imposing severance and wind-down costs. Structurally, this narrows the company's business model to clinical development, increasing execution and funding concentration risks over the medium term.
InMed Pharmaceuticals News
MWG FAQ
What was InMed Pharmaceuticals’s price range in the past 12 months?
InMed Pharmaceuticals lowest stock price was €0.60 and its highest was €6.60 in the past 12 months.
What is InMed Pharmaceuticals’s market cap?
InMed Pharmaceuticals’s market cap is €2.03M.
When is InMed Pharmaceuticals’s upcoming earnings report date?
InMed Pharmaceuticals’s upcoming earnings report date is May 18, 2026 which is in 65 days.
How were InMed Pharmaceuticals’s earnings last quarter?
InMed Pharmaceuticals released its earnings results on Feb 11, 2026. The company reported -€0.447 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.447.
Is InMed Pharmaceuticals overvalued?
According to Wall Street analysts InMed Pharmaceuticals’s price is currently Overvalued.
Does InMed Pharmaceuticals pay dividends?
InMed Pharmaceuticals does not currently pay dividends.
What is InMed Pharmaceuticals’s EPS estimate?
InMed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InMed Pharmaceuticals have?
InMed Pharmaceuticals has 2,919,186 shares outstanding.
What happened to InMed Pharmaceuticals’s price movement after its last earnings report?
InMed Pharmaceuticals reported an EPS of -€0.447 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -14.013%.
Which hedge fund is a major shareholder of InMed Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:MWG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InMed Pharmaceuticals
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Technical Analysis
Alaunos Therapeutics
―
―
Xenetic Biosciences
―
Ensysce Biosciences
―
Pasithea Therapeutics Corp
―
Options Prices
Currently, No data available
---